RenovoRx (RNXT)

• Market cap: $43.6M
• 1 day: 6.09%
• 5 days: 9.68%
• 1 month: 5.5%
• 3 months: -10.54%
• 6 months: 7.9%
• Year to date: 15.68%
• 1 year: -31.96%
• 5 years: -86.69%
• 10 years: -86.69%
• Sector: Healthcare
• Industry: Biotechnology

About: RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Employees: 17